Source: Myeloma – Hematology Advisor
Elranatamab is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody.
Read More
Recent Content
- Dr Battiwalla on Advancements in the Multiple Myeloma Treatment Paradigm
- Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma
- Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma
- Death Caused by Disseminated Herpes Zoster in a Patient with Multiple Myeloma: A Case Report and Literature Review
- Disparities in Multiple Myeloma Mortality Rate Trends by Demographic Status in the USA
- Extramedullary plasmacytoma of the orbit complicating the evolution of multiple myeloma in complete remission
- Urinary Insulin-Like Growth Factor-Binding Protein 7 (IGFBp7), Urinary Tissue Inhibitor of Matrix Metalloproteinase 2 (TIMP2), and Serum Transgelin as Novel Biomarkers of Kidney Injury in Multiple Myeloma
- Diagnosis of rare entity CD138 negative plasma cell multiple myeloma: the synergy between laboratory and clinician makes the difference
- Latent tuberculosis infection detected by quantiferon-TB assay in patients with multiple myeloma receiving novel drugs: focus on reactivation prophylaxis in a retrospective, single-center study
- Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse